Merus (NASDAQ:MRUS) Now Covered by Analysts at Roth Capital

Roth Capital assumed coverage on shares of Merus (NASDAQ:MRUS) in a research report released on Friday, June 28th, FirstToMarketsRatingsTable reports. The firm issued a buy rating and a $20.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on MRUS. Citigroup cut Biogen from a buy rating to a neutral rating and dropped their price target for the company from $470.00 to $230.00 in a research note on Thursday, March 21st. Zacks Investment Research upgraded Jack Henry & Associates from a sell rating to a hold rating in a research note on Wednesday, March 27th. Guggenheim cut Anadarko Petroleum from a buy rating to a hold rating and set a $69.00 price objective on the stock. in a research report on Friday, April 12th. Royal Bank of Canada set a €5.70 ($6.63) price objective on Banco Santander and gave the stock a buy rating in a research report on Wednesday, April 3rd. Finally, Wedbush increased their price objective on Urban Outfitters from $30.00 to $35.00 and gave the stock a hold rating in a research report on Friday, April 5th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. Merus currently has a consensus rating of Buy and an average target price of $22.57.

Shares of Merus stock traded down $0.01 on Friday, reaching $15.00. 5,345 shares of the company were exchanged, compared to its average volume of 30,681. Merus has a one year low of $11.00 and a one year high of $24.37. The firm has a market cap of $341.49 million, a P/E ratio of -8.15 and a beta of 0.22. The firm’s 50-day moving average is $14.21.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, May 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.22. Merus had a negative return on equity of 39.46% and a negative net margin of 75.71%. The business had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $7.47 million. On average, sell-side analysts predict that Merus will post -1.9 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC grew its holdings in shares of Merus by 10.3% during the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,100 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Merus by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 2,373 shares in the last quarter. Morgan Stanley boosted its stake in Merus by 74.3% in the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after buying an additional 30,538 shares in the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in Merus in the first quarter valued at about $468,000. 52.13% of the stock is currently owned by institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Recommended Story: How to use beta for portfolio diversification

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.